Frontier Economics has released a comprehensive report commissioned by EMBL's European Bioinformatics Institute that quantifies the economic value of open biodata infrastructure. The analysis treats public biological databases and data resources as foundational infrastructure comparable to roads and electricity systems in their importance to society.
The report examines how freely accessible genomic, proteomic, and other biological datasets have become indispensable tools for life sciences research globally. EMBL-EBI operates several major open data platforms that researchers worldwide use without charge, including sequence databases and protein structure repositories. These resources eliminate barriers to scientific discovery and enable researchers in under-resourced institutions and developing nations to compete on equal footing with well-funded laboratories.
Frontier Economics assessed the return on investment from maintaining and expanding these public databases. The analysis likely documents how open biodata accelerates drug discovery, supports academic research, and reduces redundant data generation across institutions. When researchers can access curated, standardized biological data freely, they avoid duplicating expensive experiments and can focus computational resources on novel analysis.
The economic framing carries particular weight in an era when funding agencies increasingly demand evidence of research impact. By demonstrating that public biodata infrastructure generates measurable economic returns relative to its maintenance costs, the report strengthens the case for sustained government and institutional investment. It also counters arguments for privatizing valuable biological databases.
Open biodata infrastructure represents a collective good. Individual researchers and companies benefit without bearing the full costs of data collection, quality control, and long-term stewardship. The market alone would under-provide these services because private entities cannot fully capture the value they generate. Public funding of EMBL-EBI and similar organizations corrects this market failure.
The report's framing of biodata as infrastructure reflects a maturation in how the scientific community values data resources. Rather than treating databases as peripheral research tools, the analysis positions them as backbone systems that enable the